Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The global health community has set itself the task of eliminating tuberculosis (TB) as a public health problem by 2050. Although progress has been made in global TB control, the current decline in incidence of 2% yr(-1) is far from the rate needed to achieve this. If we are to succeed in this endeavour, new strategies to reduce the reservoir of latently infected persons (from which new cases arise) would be advantageous. However, ascertainment of the extent and risk posed by this group is poor. The current diagnostics tests (tuberculin skin test and interferon-gamma release assays) poorly predict who will develop active disease and the therapeutic options available are not optimal for the scale of the intervention that may be required. In this article, we outline a basis for our current understanding of latent TB and highlight areas where innovation leading to development of novel diagnostic tests, drug regimens and vaccines may assist progress. We argue that the pool of individuals at high risk of progression may be significantly smaller than the 2.33 billion thought to be immune sensitized by Mycobacterium tuberculosis and that identifying and targeting this group will be an important strategy in the road to elimination.

Original publication

DOI

10.1098/rstb.2013.0437

Type

Journal article

Journal

Philos Trans R Soc Lond B Biol Sci

Publication Date

2014

Volume

369

Keywords

Mycobacterium tuberculosis, diagnosis, elimination, latent tuberculosis, natural history, treatment, Adaptation, Physiological, Disease Eradication, Global Health, History, 20th Century, History, 21st Century, Humans, Latent Tuberculosis, Mycobacterium tuberculosis, Risk Factors, Tuberculin Test